Over 15 pharma companies advance 20+ synovial sarcoma drugs in clinical trials, boosting treatment hopes.
More than 15 pharmaceutical companies are actively developing over 20 drugs for synovial sarcoma, a rare and aggressive cancer. Key players like Takara Bio, Immatics, and ModernaTX are testing promising therapies in various clinical trial phases, inc...
